Article Information
History
- July 16, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Veronica Urdaneta, MD, MPH1,
- Daina B. Esposito, MPH, PhD2,
- Priyadarshani Dharia, MD, MPH, PhD2,
- Margot Stam Moraga, MSc, MPH1,
- Kate Anteyi, MD, MPH, MBA1,
- Titi Oduyebo-Omotosho, MD, MPH1,
- Melissa Rossi, MPH1,
- Paul Burton, MD, PhD2,3,
- José M. Vega, MD3,
- Rachel Dawson, DO, MPH2 and
- Walter Straus, MD, MPH3,*
- 1Clinical Safety and Risk Management, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
- 2Medical Affairs, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
- 3Clinical Safety and Pharmacovigilance, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
- ↵*Corresponding Author:
Walter Straus, 200 Technology Square Cambridge, MA 02139, USA, Phone: 617-899-3283, Email: walter.straus{at}modernatx.com
Posted July 16, 2023.
Global Safety Assessment of Adverse Events of Special Interest Following 2 Years of Use and 772 Million Administered Doses of mRNA-1273
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos